Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy

Fig. 5

Response prediction value of ctDNA dynamics during treatment. A, B Kaplan–Meier estimates of PFS (A) and OS (B) according to the percent changes of C2 ctDNA level relative to baseline (N = 31). C, D Kaplan–Meier estimates of PFS (C) and OS (D) according to interim ctDNA clearance status at the end of C4 (N = 38). E, F Kaplan–Meier estimates show the PFS (E) and OS (F) of patients based on the combination of interim PET-CT and ctDNA clearance status (N = 38). Patients are divided into three groups: negative interim PET-CT and ctDNA clearance (− / −), positive interim PET-CT and positive ctDNA (+ / +), and either positive interim PET-CT or positive ctDNA (+ / −)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us